| HOME >> MEDICINE >> TECHNOLOGY |
Net loss $(45,119) $3,416 $(41,703)
Basic and diluted net loss per
share $(1.58)
Shares used to compute basic
and diluted net loss per share 28,605
[1] Reflects operating results in accordance with U.S. generally accepted
accounting principles (or GAAP).
[2] Represents share-based compensation expense.
[3] Non-GAAP amounts exclude share-based compensation expense.
Alexza Pharmaceuticals, Inc.
(a development stage company)
Condensed Consolidated Statements of Operations
(in thousands except per share data)
Year Ended
December 31, 2006
GAAP [1] Difference [2] Non-GAAP [3]
Revenue $1,028 $- $1,028
Operating expenses
Research and development 36,494 (1,770) 34,724
General and administrative 9,969 (447) 9,522
Total operating expenses 46,463 (2,217) 44,246
Loss from operations (45,435) 2,217 (43,218)
Interest and other income, net 2,687 - 2,687
Interest expense (778) - (778)
Loss before non-controlling
interest in Symphony Allegro,
Inc. (43,526) 2,217 (41,309)
Loss attributed to
non-controlling interest in
Symphony Allegro, Inc. 1,720 - 1,720
Net loss $(41,806) $2,217 $(39,589)
Basic and diluted net loss per
'/>"/>| SOURCE Alexza Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |